<DOC>
	<DOCNO>NCT02368951</DOCNO>
	<brief_summary>To evaluate safety , tolerability , maximum tolerate dose , pharmacokinetics , pharmacodynamics anti-FGFR2 antibody drug conjugate BAY1187982 subject advanced solid tumor know express fibroblast growth factor receptor 2 ( FGFR2 )</brief_summary>
	<brief_title>Phase I , Dose-escalation Trial BAY1187982 Subjects With Advanced Solid Tumors Known Express Fibroblast Growth Factor Receptor 2 ( FGFR2 )</brief_title>
	<detailed_description />
	<mesh_term>Mitogens</mesh_term>
	<criteria>All subject must &gt; /= 18 year first screen examination / visit Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Subjects advance , histologically cytologically confirm solid tumor describe express fibroblast growth factor receptor 2 ( FGFR2 ) refractory standard therapy For maximum tolerate dose ( MTD ) Dose Expansion : Subjects advance , histologically cytologically confirm triplenegative breast cancer undergone within 4 line systemic anticancer treatment eligible standard therapy anymore . Subjects need evaluable disease ( measurable measurable ) . Women childbearing potential must negative pregnancy test perform within 7 day prior start treatment History allergic reaction monoclonal antibody therapy ( excipients formulation ) Anticancer chemotherapy , experimental cancer therapy include clinical trial , cancer immunotherapy within 4 week prior first dose investigational drug . Toxic effect previous anticancer chemotherapy , experimental cancer therapy , cancer immunotherapy normalize . History symptomatic metastatic brain meningeal tumor unless subject long 3 month end definitive therapy first dose investigational drug clinically radiologically evidence tumor growth . History clinically significant cardiac disease Congenital coagulation abnormality Subjects pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>FGFR2</keyword>
	<keyword>Antibody drug conjugate</keyword>
</DOC>